Published on
Nov 25, 2024
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
Just three days after approving BridgeBio’s Attruby for transthyretin amyloid cardiomyopathy, the FDA has accepted Alnylam’s application to expand Amvuttra’s label to cover the rare cardiovascular disease. Taken together, the decisions signal potentially …
Source:
BioSpace
-
Label Pending
